Search

Your search keyword '"Kemeny, Nancy E."' showing total 383 results
Start Over Author "Kemeny, Nancy E." Language english
383 results on '"Kemeny, Nancy E."'

1. Adjuvant Cytotoxic Chemotherapy may not be Associated with a Survival Advantage for Resected Intrahepatic Cholangiocarcinoma

Author

Sharib, Jeremy, Rhodin, Kristen E., Liu, Annie, McIntyre, Sarah, Bartholomew, Alex, Masoud, Sabran, DeLaura, Isabel, Kemeny, Nancy E., Cercek, Andrea, Harding, James J., O’Reilly, Eileen M., Abou-Alfa, Ghassan K., Reidy-Lagunes, Diane, Connell, Louise Catherine, Dika, Imane El, Balachandran, Vinod P., Drebin, Jeffrey, Soares, Kevin C., Wei, Alice C., Kingham, T. Peter, D’Angelica, Michael I., Uronis, Hope, Strickler, John, Hsu, S. David, Morse, Michael, Zani, Sabino, Allen, Peter J., Jarnagin, William R., and Lidsky, Michael E.

Published
2025
Full Text
View/download PDF

2. ASO Visual Abstract: Adjuvant Cytotoxic Chemotherapy May Not Be Associated with a Survival Advantage for Resected Intrahepatic Cholangiocarcinoma

Author

Sharib, Jeremy, Rhodin, Kristen E., Liu, Annie, McIntyre, Sarah, Bartholomew, Alex, Masoud, Sabran, DeLaura, Isabel, Kemeny, Nancy E., Cercek, Andrea, Harding, James J., O’Reilly, Eileen M., Abou-Alfa, Ghassan K., Reidy-Lagunes, Diane, Connell, Louise Catherine, El Dika, Imane, Balachandran, Vinod P., Drebin, Jeffrey, Soares, Kevin C., Wei, Alice C., Kingham, T. Peter, D’Angelica, Michael I., Uronis, Hope, Strickler, John, Hsu, S. David, Morse, Michael, Zani, Sabino, Allen, Peter J., Jarnagin, William R., and Lidsky, Michael E.

Published
2025
Full Text
View/download PDF

3. Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma

Author

Franssen, Stijn, Holster, Jessica J., Jolissaint, Joshua S., Nooijen, Lynn E., Cercek, Andrea, D’Angelica, Michael I., Homs, Marjolein Y. V., Wei, Alice C., Balachandran, Vinod P., Drebin, Jeffrey A., Harding, James J., Kemeny, Nancy E., Kingham, T. Peter, Klümpen, Heinz-Josef, Mostert, Bianca, Swijnenburg, Rutger-Jan, Soares, Kevin C., Jarnagin, William R., and Groot Koerkamp, Bas

Published
2024
Full Text
View/download PDF

5. Extrahepatic perfusion and incomplete hepatic perfusion after hepatic arterial infusion pump implantation: incidence and clinical implications

Author

Filipe, Wills F., Buisman, Florian Buismanz, Koerkamp, Bas Groot, Grunhagen, Dirk J., Homs, Marjolein Y.V., Verhoef, Cornelis, Moelker, Adriaan, Graven, Laura, Franssen, Stijn, Gobardhan, Paul D., Loosveld, Olaf J.L., Pool, Stefan, Mieog, J. Sven D., Speetjens, Frank M., Rietbergen, Daphne D.D., Burgmans, Mark C., Doornesbosch, Pascal G., Patijn, Gijs A., de Groot, Jan Willem B., Meier, Mark A.J., Oostdijk, Ad H.J., Boluis, Karen, Grootscholten, Cecile, klompenhouwer, Elizabeth G., Kok, Niels F.M., kuhlmann, Koert, F.D., Krul, Myrtle F., Versleijen, Michelle W.J., Bruijnen, Rutger C.G., Hagendoorn, Jroen, Lam, Marnix G.E.H., Roodhart, Jeanine M.L., Bennink, Roel J., van Delden, Otto M., Swijnenburg, Rutger-Jan, Buffart, Tineke E., Borel Rinkes, Inne H.M., Cercek, Andrea, Kemeny, Nancy E., Peter Kingham, T., D’Angelica, Michael, van Bommel, Christian P.H., van Doorn, Leni, Ayez, Ninos, Vermaas, Maarten, Nieuwenhuijse, Vincent B., Buisman, Florian E., Grünhagen, Dirk J., Bolhuis, Karen, Doornebosch, Pascal G., Hagendoorn, Jeroen, Harmsen, Paul, Klompenhouwer, Elizabeth G., Outmani, Loubna, Swijnenburg, Rutger Jan, Kuhlmann, Koert F.D., and Groot Koerkamp, Bas

Published
2024
Full Text
View/download PDF

7. ASO Visual Abstract: Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma

Author

Franssen, Stijn, Holster, Jessica J., Jolissaint, Joshua S., Nooijen, Lynn E., Cercek, Andrea, D’Angelica, Michael I., Homs, Marjolein Y. V., Wei, Alice C., Balachandran, Vinod P., Drebin, Jeffrey A., Harding, James J., Kemeny, Nancy E., Kingham, T. Peter, Klümpen, Heinz-Josef, Mostert, Bianca, Swijnenburg, Rutger-Jan, Soares, Kevin C., Jarnagin, William R., and Groot Koerkamp, Bas

Published
2024
Full Text
View/download PDF

9. Genomic Predictors of Recurrence Patterns After Complete Resection of Colorectal Liver Metastases and Adjuvant Hepatic Artery Infusion Chemotherapy

Author

Narayan, Raja R., Datta, Jashodeep, Goldman, Debra A., Aveson, Victoria G., Walch, Henry S., Sanchez-Vega, Francisco, Gönen, Mithat, Balachandran, Vinod P., Drebin, Jeffrey A., Jarnagin, William R., Kingham, T. Peter, Wei, Alice C., Schultz, Nikolaus, Kemeny, Nancy E., and D’Angelica, Michael I.

Published
2022
Full Text
View/download PDF

13. Factors Associated With Local Tumor Control and Complications After Thermal Ablation of Colorectal Cancer Liver Metastases: A 15-year Retrospective Cohort Study

Author

Kurilova, Ieva, Bendet, Achiude, Petre, Elena N., Boas, Franz E., Kaye, Elena, Gonen, Mithat, Covey, Anne, Brody, Lynn A., Brown, Karen T., Kemeny, Nancy E., Yarmohammadi, Hooman, Ziv, Etay, D’Angelica, Michael I., Kingham, T. Peter, Cercek, Andrea, Solomon, Steven B., Beets-Tan, Regina G.H., and Sofocleous, Constantinos T.

Published
2021
Full Text
View/download PDF

17. Distinct Genomic Profiles are Associated With Conversion to Resection and Survival in Patients With Initially Unresectable Colorectal Liver Metastases Treated With Systemic and Hepatic Artery Chemotherapy

Author

Datta, Jashodeep, Narayan, Raja R., Goldman, Debra A., Chatila, Walid K., Gonen, Mithat, Strong, James, Balachandran, Vinod P., Drebin, Jeffrey A., Kingham, T. Peter, Jarnagin, William R., Schultz, Nikolaus, Kemeny, Nancy E., and D’Angelica, Michael I.

Published
2022
Full Text
View/download PDF

18. Recurrence After Liver Resection of Colorectal Liver Metastases: Repeat Resection or Ablation Followed by Hepatic Arterial Infusion Pump Chemotherapy

Author

Buisman, Florian E., Filipe, Wills F., Kemeny, Nancy E., Narayan, Raja R., Srouji, Rami M., Balachandran, Vinod P., Boerner, Thomas, Drebin, Jeffrey A., Jarnagin, William R., Kingham, T. Peter, Wei, Alice C., Grünhagen, Dirk J., Verhoef, Cornelis, Koerkamp, Bas Groot, and D’Angelica, Michael I.

Published
2021
Full Text
View/download PDF

23. Distinct Genomic Profiles are Associated With Conversion to Resection and Survival in Patients With Initially Unresectable Colorectal Liver Metastases Treated With Systemic and Hepatic Artery Chemotherapy

Author

Datta, Jashodeep, Narayan, Raja R., Goldman, Debra A., Chatila, Walid K., Gonen, Mithat, Strong, James, Balachandran, Vinod P., Drebin, Jeffrey A., Kingham, T. Peter, Jarnagin, William R., Schultz, Nikolaus, Kemeny, Nancy E., and D’Angelica, Michael I.

Published
2020
Full Text
View/download PDF

25. Adjuvant Hepatic Arterial Infusion Pump Chemotherapy After Resection of Colorectal Liver Metastases: Results of a Safety and Feasibility Study in The Netherlands

Author

Buisman, Florian E., Grünhagen, Dirk J., Homs, Marjolein Y. V., Grootscholten, Cecile, Filipe, Wills F., Kemeny, Nancy E., Cercek, Andrea, D’Angelica, Micheal I., Donswijk, Maarten L., van Doorn, Leni, Emmering, Jasper, Jarnagin, William R., Kingham, T. Peter, Klompenhouwer, Elisabeth G., Kok, Niels F. M., Kuiper, Maria C., Moelker, Adriaan, Prevoo, Warner, Versleijen, Michelle W. J., Verhoef, Cornelis, Kuhlmann, Koert F. D., and Groot Koerkamp, Bas

Published
2019
Full Text
View/download PDF

29. Hepatic arterial infusion pump chemotherapy combined with systemic chemotherapy for borderline resectable and unresectable colorectal liver metastases: phase II feasibility study.

Author

Krul, Myrtle F, Kok, Niels F M, Osmani, Harun, Buisman, Florian E, Groot Koerkamp, Bas, Grunhagen, Dirk J, Verhoef, Cornelis, Mostert, Bianca, Snaebjornsson, Petur, Westerink, Bram, Klompenhouwer, Elisabeth G, Donswijk, Maarten L, Ruers, Theo J M, Douma, Joeri A J, van Blijderveen, Nico, Kingham, T Peter, D'Angelica, Michael I, Kemeny, Nancy E, Bolhuis, Karen, and Buffart, Tineke E

Subjects
CANCER chemotherapy, COLORECTAL liver metastasis, CHEMOEMBOLIZATION, CLINICAL trials, FEASIBILITY studies, TUMOR surgery
Abstract

Background: Hepatic arterial infusion pump chemotherapy combined with systemic chemotherapy (HAIP-SYS) for liver-only colorectal liver metastases (CRLMs) has shown promising results but has not been adopted worldwide. This study evaluated the feasibility of HAIP-SYS in the Netherlands. Methods: This was a single-arm phase II study of patients with CRLMs who received HAIP-SYS consisting of floxuridine with concomitant systemic FOLFOX or FOLFIRI. Main inclusion and exclusion criteria were borderline resectable or unresectable liver-only metastases, suitable arterial anatomy and no previous local treatment. Patients underwent laparotomy for pump implantation and primary tumour resection if in situ. Primary end point was feasibility, defined as ≥70% of patients completing two cycles of HAIP-SYS. Sample size calculations led to 31 patients. Secondary outcomes included safety and tumour response. Results: Thirty-one patients with median 13 CRLMs (i.q.r. 6–23) were included. Twenty-eight patients (90%) received two HAIP-SYS cycles. Three patients did not get two cycles due to extrahepatic disease at pump placement, definitive pathology of a recto-sigmoidal squamous cell carcinoma, and progressive disease. Five patients experienced grade 3 surgical or pump device-related complications (16%) and 11 patients experienced grade ≥3 chemotherapy toxicity (38%). At first radiological evaluation, disease control rate was 83% (24/29 patients) and hepatic disease control rate 93% (27/29 patients). At 6 months, 19 patients (66%) had experienced grade ≥3 chemotherapy toxicity and the disease control rate was 79%. Conclusion: HAIP-SYS for borderline resectable and unresectable CRLMs was feasible and safe in the Netherlands. This has led to a successive multicentre phase III randomized trial investigating oncological benefit (EUDRA-CT 2023–506194-35-00). Current trial registration number: clinicaltrials.gov (NCT04552093). Treatment of unresectable or borderline-resectable CRLMs with hepatic arterial infusion pump chemotherapy (floxuridine) combined with systemic chemotherapy (FOLFOX or FOLFIRI) is feasible and safe in the Netherlands. These results have led to a subsequent multicentre phase III randomized trial investigating the oncological benefit of this combined therapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Intrahepatic cholangiocarcinoma: Recurrence patterns, genomics and survival.

Author

Chandra, Pratik, Song, Yi, Drill, Esther N., Wei, Alice Chia-Chi, Kemeny, Nancy E., Cercek, Andrea, Connell, Louise Catherine, Harding, James J., Abou-Alfa, Ghassan K., Park, Wungki, Kingham, T. Peter, Soares, Kevin, Balachandran, Vinod P., Drebin, Jeffrey A., D'Angelica, Michael Ian, O'Reilly, Eileen Mary, Groot Koerkamp, Bas, and Jarnagin, William R.

Published
2024
Full Text
View/download PDF

34. Salvage hepatic artery infusion chemotherapy after first-line systemic failure in patients with unresectable cholangiocarcinoma.

Author

Nasar, Naaz, Armstrong, Misha, Chou, Joanne F., Gonen, Mithat, Soares, Kevin, Balachandran, Vinod P., Drebin, Jeffrey A., Kingham, T. Peter, Wei, Alice Chia-Chi, D'Angelica, Michael Ian, Cercek, Andrea, Harding, James J., O'Reilly, Eileen Mary, Abou-Alfa, Ghassan K., Park, Wungki, Connell, Louise Catherine, Kemeny, Nancy E., and Jarnagin, William R.

Published
2024
Full Text
View/download PDF

44. Hepatic disease control in patients with intrahepatic cholangiocarcinoma correlates with overall survival.

Author

Soares, Kevin C., Jolissaint, Joshua S., McIntyre, Sarah M., Seier, Kenneth P., Gönen, Mithat, Sigel, Carlie, Nasar, Naaz, Cercek, Andrea, Harding, James J., Kemeny, Nancy E., Connell, Louise C., Koerkamp, Bas Groot, Balachandran, Vinod P., D'Angelica, Michael I., Drebin, Jeffrey A., Kingham, T. Peter, Wei, Alice C., and Jarnagin, William R.

Subjects
OVERALL survival, CHOLANGIOCARCINOMA, PREVENTIVE medicine, CANCER chemotherapy, PROPENSITY score matching, HEPATIC veno-occlusive disease
Abstract

Purpose: The role of locoregional therapy compared to systemic chemotherapy (SYS) for unresectable intrahepatic cholangiocarcinoma (IHC) remains controversial. The importance of hepatic disease control, either as initial or salvage therapy, is also unclear. We compared overall survival (OS) in patients treated with resection, hepatic arterial infusion pump (HAIP) chemotherapy, or SYS as it relates to hepatic recurrence or progression. We also evaluated recurrence after resection to determine the efficacy of locoregional salvage therapy. Patients and Methods: In this single‐institution retrospective analysis, patients with biopsy‐proven IHC treated with either curative‐intent resection, HAIP (with or without SYS), or SYS alone were analyzed. Propensity score matching (PSM) was used to compare patients with liver‐limited, advanced disease treated with HAIP versus SYS. The impact of locoregional salvage therapies in patients with liver‐limited recurrence was analyzed in the resection cohort. Results: From 2000 to 2017, 714 patients with IHC were treated, 219 (30.7%) with resectable disease, 316 (44.3%) with locally advanced disease, and 179 (25.1%) with metastatic disease. Resected patients were less likely to recur or progress in the liver (hazard ratio [HR] 0.41, 95% CI 0.34–0.45) versus those that received HAIP or SYS (HR 0.58, 95% CI 0.50–0.65 vs. HR 0.63, 95% CI 0.57–0.69, respectively). In resected patients, 161 (64.4%) recurred, with 65 liver‐only recurrences. Thirty of these patients received subsequent locoregional therapy. On multivariable analysis, locoregional therapy was associated with improved OS after isolated liver recurrence (HR 0.46, 95% CI 0.29–0.75; p = 0.002). In patients with locally advanced unresectable or multifocal liver disease (with or without distant organ metastases), PSM demonstrated improved hepatic progression‐free survival in patients treated with HAIP versus SYS (HR 0.65; 95% CI 0.46–0.91; p = 0.01), which correlated with improved OS (HR 0.59, 95% CI 0.43–0.80; p < 0.001). Conclusion: In patients with liver‐limited IHC, hepatic disease control is associated with improved OS, emphasizing the potential importance of liver‐directed therapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

45. PET-based compartmental modeling of 124I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer

Author

Zanzonico, Pat, Carrasquillo, Jorge A., Pandit-Taskar, Neeta, O’Donoghue, Joseph A., Humm, John L., Smith-Jones, Peter, Ruan, Shutian, Divgi, Chaitanya, Scott, Andrew M., Kemeny, Nancy E., Fong, Yuman, Wong, Douglas, Scheinberg, David, Ritter, Gerd, Jungbluth, Achem, Old, Lloyd J., and Larson, Steven M.

Published
2015
Full Text
View/download PDF

50. Regional Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Potential Role for Dynamic Magnetic Resonance Imaging as an Imaging Biomarker and a Survival Update from Two Prospective Clinical Trials

Author

Konstantinidis, Ioannis T., Do, Richard K. G., Gultekin, David H., Gönen, Mithat, Schwartz, Lawrence H., Fong, Yuman, Allen, Peter J., D’Angelica, Michael I., DeMatteo, Ronald P., Klimstra, David S., Kemeny, Nancy E., and Jarnagin, William R.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results